Saudi Arabia Cough Hypersensitivity Syndrome Therapeutics Market Analysis

Saudi Arabia Cough Hypersensitivity Syndrome Therapeutics Market Analysis Executive Summary

The Saudi Arabia Cough Hypersensitivity Syndrome Therapeutics Market is at around $138 Mn in 2022 and is projected to reach $244 Mn in 2030, exhibiting a CAGR of 7.4% during the forecast period.

Cough Hypersensitivity Syndrome (CHS) is indicated by an excessive response to stimuli, causing an increased sensitivity to the cough reflex. This results in frequent coughing in response to numerous irritants such as dust, fragrances, and cold air. Common causes of CHS include respiratory infections, gastroesophageal reflux disease (GERD), and exposure to environmental toxins. Symptoms include a persistent cough, with an underlying respiratory disorder, and throat irritation, or discomfort. Cough Hypersensitivity Syndrome is effectively treated by addressing the underlying reasons and regulating the heightened cough reflex. Available treatments include antitussives, which suppress the cough reflex, and those that target underlying disorders such as GERD. Companies like GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim manufacture drugs for CHS.

Chronic cough which can cause CHS affects around 8% of the population in Saudi Arabia. The market is driven by major contributors such as the rising prevalence of Cough Hypersensitivity Syndrome and subsequently its risk factors like smoking and pollution, development of advanced therapeutics, and supportive government policies. However, conditions such as limited treatment alternatives, lack of human resources, and minimum local research and development restrict the growth and potential of the market.

Market Dynamics

Market Growth Drivers

Surge in prevalence of Cough Hypersensitivity Syndrome: Conditions such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis, which fall under the category of chronic respiratory diseases, significantly contribute to the occurrence of Cough Hypersensitivity Syndrome (CHS). Chronic cough is highly prevalent in Saudi Arabia affecting around 8% of the population. The prevalence of these respiratory diseases is on the rise in Saudi Arabia, leading to an expanding patient population in need of CHS treatment and consequently fuelling market growth. Air pollution, smoking, and urbanization are correlated to a rise in the prevalence of chronic respiratory disorders.

Development of advanced therapeutics: Pharmaceutical companies are developing enhanced CHS drugs, to provide patients with effective and targeted therapy alternatives. This approach allows more people to seek treatment, therefore supporting market growth. The emphasis is on developing drugs with reduced side effects, prolonged efficacy, and targeted therapies tailored to specific subtypes of CHS.

Supportive government initiatives: Increased healthcare investments in Saudi Arabia are enhancing access to diagnostic tools and specialist consultations, facilitating earlier and more precise diagnoses of CHS. Government-led initiatives such as the Saudi Arabia Thoracic Society (STS) encourage awareness campaigns, educate the public about the symptoms of CHS, and promote timely medical attention.

Market Restraints

Limited treatment alternatives: At present, the Saudi Food and Drug Authority (SFDA) has not approved any medications specifically designed for Cough Hypersensitivity Syndrome (CHS). This constraint encourages the use of off-label medications with potential adverse effects. The process of developing and obtaining permission for CHS-specific medications is a lengthy and time-consuming process with delays in timely treatment for patients.

Workforce shortage: A shortage of pulmonologists, allergists, and other experts with competence in diagnosing and managing CHS causes delays in receiving early and appropriate therapy. This gap in services reduces the growth of the market.

Limited local research and development: The smaller patient population in comparison to other respiratory disorders discourages heavy investment in CHS therapeutics. A lack of understanding of CHS restricts the development of more precise and effective treatments.

Healthcare Policies and Regulatory Landscape

The Saudi Food and Drug Authority (SFDA) is the primary regulating authority for medications and pharmaceuticals in Saudi Arabia. Established in 2003, the SFDA is in charge of ensuring the safety, efficacy, and quality of drugs in KSA. The SFDA follows international norms and recommendations and the authority is responsible for the approval and licensing of pharmaceutical products, as well as their marketing in the country.

To get drug licenses in Saudi Arabia, manufacturers submit an application to the SFDA including detailed information on the product specifications. To guarantee regulatory compliance, the SFDA assesses provided data and reviews manufacturing procedures. Once approved, a product can be sold in the Saudi market.

The regulatory environment for new entrants involves a rigorous evaluation process to ensure the safety and quality of pharmaceutical products entering the market, creating a level playing field and maintaining high standards in the healthcare sector. Companies seeking entry must navigate these regulatory requirements to gain approval for their products in Saudi Arabia.

Competitive Landscape

Key Players

• Pfizer
• GlaxoSmithKline
• Boehringer Ingelheim
• AstraZeneca
• F. Hoffman-La Roche Ltd
• Sanofi
• Novartis
• Merck
• Almirall SA
• Johnson & Johnson